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 Distinct quiescent states exist in the hematopoietic stem cell (HSC) pool to maintain 
life-long function. 
 The CDK4/CDK6/Cyclin D complex is key to maintain the balance between HSC 
quiescence and division. 
 The kinetics of quiescence exit and early G1 influence HSC differentiative output ex 
vivo. 
 Modulating the quiescence to division kinetics has key implications for HSC expansion 
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A trillion blood cells are produced daily to maintain blood function at steady state. This 
immense regenerative output is achieved by the concerted action of rare and infrequently 
dividing hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs). Decades of 
work, primarily from mouse models, have built complex roadmaps of the first steps of 
hematopoiesis by dissecting the cascade of cell divisions occurring from the most potent HSCs 
to multi- and in turn unilineage progenitors. Recently, single cell RNA-seq and clonal tracking 
have complemented these by defining differentiation trajectories at single cell resolution [1]. 
All evidence to date agrees that unilineage progenitor cell types typically divide continuously, 
re-entering G1 after mitosis. In contrast, HSCs and MPPs do not; they divide occasionally, 
spending the majority of their cellular life outside of the cell cycle, in a reversible state termed 
quiescence or G0. As HSCs and MPPs largely differ at single cell resolution in their self-renewal 
capacity and lineage preferences [1], this places quiescence as the only fundamental common 
property of all HSC/MPPs.  
 
Quiescence can be conceptualized as a poised, restrained and actively maintained molecular 
state [2]. Classical hallmarks of quiescence are shared by many adult stem cell types and 
include low protein synthesis and reliance on glycolytic metabolism. Consistently, in vivo, the 
maintenance of HSCs in quiescence relies on a specific metabolic context and organelle 
biology. Initially thought to have low mitochondrial mass, quiescent HSCs are now known to 
contain relatively high numbers of inactive mitochondria [3] with an abundance of large 
inactive lysosomes [4]. Long-term maintenance of HSC potency is reliant on restrained 
glycolytic metabolism [4,5], and a balanced metabolic state maintained by autophagic 
recycling [6,7]. Protein synthesis rates are low in quiescent HSCs [8,9], yet there are high 
thresholds of protein quality control ensured by high basal expression of Endoplasmic 
Reticulum Associated Degradation (ERAD) [10,11]  and Integrated Stress Response pathways 
[12,13]. Similarly, cellular responses to DNA damage are distinct in HSCs compared to 
progenitors [14,15]. A consequence of the longevity of HSCs is the accumulation of genotoxic, 
proteotoxic and oxidative stress damage which, in absence of cell division, cannot be 
distributed to progeny. Quiescent HSCs are thus wired to maintain the highest standards of 
genomic, proteostatic and organelle integrity resulting in preferential culling of damaged 
HSCs to mitigate the risk of leukemic transformation and reduced HSC pool fitness.  
 
Maintenance of HSC quiescence, exit from quiescence, division and subsequent return to 
quiescence must be tightly controlled. This balance has emerged to be intimately linked to 
HSC function. In the past decade, single cell resolution and novel tools have shown that the 
overall picture is complex and cannot be oversimplified to: “HSCs are either more quiescent 
or more proliferative” in the particular instance studied. Here we focus on a few important 
findings that have emerged from these studies. We provide definitions and a framework in 
which to interpret the complex relationship between quiescence, cell cycle kinetics and HSC 
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fate choices; a key step towards new translational opportunities for HSC expansion, 
transplantation and gene therapy.  
 
 
Quiescence is a collection of actively maintained cellular states 
 
In hierarchically organised stem cell systems such as blood, muscle [16] and the 
subventricular zone of the brain [17], there is now ample evidence that quiescence is not a 
uniform state and that varying depths of quiescence allow cells to differently and 
appropriately contribute to tissue maintenance and regeneration. Across all these tissues, the 
most immature stem cells reside in a deeper quiescent state than their progeny. Depth of 
quiescence is primarily measured via the time a cell takes to exit this state upon receiving a 
mitogenic stimulus (quiescence exit: from G0 to end of early G1), often approximated to the 
time of first division ex vivo. Quiescence is an integral state existing in a wide range of 
organisms; there is much to be learnt from seminal work in bacteria, yeast and cell lines that 
applies to adult stem cells, including HSCs.  
 
First, protein levels of the CDK4/CDK6 complex are a faithful reporter of quiescence depth. 
CDK4/CDK6 activation is the key trigger for cells to enter G1 whether they have just divided 
(from M to G1) or have been quiescent for a given period of time (from G0 to G1). CDK4/CDK6 
activity sustains retinoblastoma protein (Rb) hyperphosphorylation in early G1, which is 
necessary for a cell to pass the restriction point (R point)  and commit to division [18]. In 
human and mouse HSCs, CDK6 levels govern the degree to which a cell is primed to respond 
to a mitogenic stimulus. Quiescent long-term HSCs (LT-HSCs, capable of forming blood over 
serial transplantation) possess undetectable levels of CDK6 protein, whereas quiescent short-
term HSCs (ST-HSCs, with transient regenerative potential upon transplantation) express 
higher CDK6 protein levels to allow faster cell cycle entry following mitogenic stimulation 
[19,20] (Figure 1) . Recent work has shown that reaching the R point is best described as a 
probabilistic process dependent on levels of CDK4/CDK6 activity in single cells [21]. This 
implies that for a specific level of mitogenic stimulus, cells with high levels of CDK4/CDK6 such 
as ST-HSCs have a higher probability of commitment to division than cells with low levels (like 
LT-HSCs). It is thus tempting to speculate that LT-HSCs may also require a stronger/longer 
mitogenic stimulus in order to divide. LT-HSCs may also be more likely to return to quiescence, 
as inhibition of CDK4/CDK6 is required for cells to return to G0 after mitosis [22]. In any case, 
maintenance of distinct depths of quiescence in LT-HSCs and ST-HSCs and the associated 
division kinetics are necessary to control HSC pool size and effective tissue regeneration [20].  
 
Second, distinct stressors can induce metabolically different states of quiescence in yeast and 
bacteria [23,24]. It is therefore unsurprising that alternative states of quiescence are also 
rendered accessible by injury in mammals. Neural stem cells exist in graded states of 
activation with characteristic metabolic profiles and acquire a primed-state of quiescence 
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after ischemia [17]. Similarly, quiescent muscle stem cells sensing an injury in a distant muscle 
can reversibly switch into a cell-cycle primed “Galert” phase, marked by mTORC1 activation, 
where cells are quiescent but possess enhanced tissue regeneration properties [16]. Mouse 
HSCs can access an mTORC1-high “Galert” state following injury, priming them to divide faster 
upon successive challenges for example with interferon-gamma [16]. The “Galert” phase is 
distinct from the primed quiescent state of ST-HSCs, that actually shows minimal levels of 
mTORC1 activity [20]. The molecular mechanisms as well as the range of stimuli that push 
HSCs into “Galert” remain to be studied. Nevertheless, these data demonstrate that specific 
quiescent states may provide at least transient cellular memory for stem cells to respond 
more efficiently to subsequent injury signals. Given recent evidence of long-term epigenetic 
memory of mouse HSCs to inflammatory signals [25,26], it will be interesting to study if and 
how alternative quiescent states play a role in such responses.  
 
Finally, a molecular checkpoint that separates the end of G0 from the beginning of G1 has not 
been identified to date in any organism.  Such a checkpoint may very well not exist and the 
transition from quiescence to early G1 may instead occur over a continuum of molecular 
states, with increasing activation of G1 genes and gradual establishment of a distinct 
metabolic activity to that of quiescence. Consistently, in the mouse, there is a continuum of 
transcriptional activation from dormant HSCs to quiescent cell-cycle primed HSCs to cell-cycle 
active HSCs [19]. Whether this activation continuum corresponds to that of the lineage-
bias/restriction observed in the HSC/MPP compartment at single cell level [27,28] remains to 
be explored.  
 
 
All HSC/MPPs are quiescent but very few are truly dormant  
 
All HSC/MPPs predominantly reside in G0 and divide much more infrequently than 
progenitors (approximately once every 30 days compared to once every 1-2 days for the 
latter). Dormant HSCs are defined as the subset of HSCs which reside in the deepest state of 
quiescence, divide the most infrequently (Figure 1) and have long been exclusively defined 
functionally, using inducible label retention assays in mice. These studies have allowed careful 
analysis of the heterogeneity in division frequencies observed in HSCs and MPPs in vivo under 
homeostatic and stress conditions. Dormancy correlates with the longest duration of 
quiescent exit and the highest degree of long term repopulation capacity [19,20,29–33]. In 
fact, the correlation is so strong that both long quiescence exit duration and extremely 
infrequent divisions can be used as surrogate markers for the long-term repopulation capacity 
of an HSC. The dormant HSC subset in mouse cycles less than once every 120 days [33], has 
superior serial repopulation capacity to all other HSC/MPP subsets and is only recruited into 
cycling upon transplantation or severe stress [19,33]. Only recently, reporter mice allowing 
prospective identification of dormant HSCs have been developed. These respectively trace 
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dormant HSCs based on either Gprc5c expression [19], p27 activity [34] or retinoic acid 
signalling [35].  
 
Self-renewal capacity has been suggested to decline with each successive division, with 
dormant HSCs becoming less likely to return to quiescence [29,31]. The number of symmetric 
divisions sufficient to exhaust self-renewal capacity is still under debate [29,36]. Extrinsic 
stresses such as those induced by 5-FU [33], LPS [32] or pI-pC [19] to mimic bacterial and viral 
infections, force dormant HSCs to re-enter the cell cycle and become activated. Importantly, 
injury activated HSCs are later able to return to dormancy and restored proportions of 
dormant HSCs can be detected within days of the initial stress signal [19,33]. However, a 
recent study has shown that HSCs permanently accumulate dysfunctional mitochondria upon 
return to quiescence [37], providing mechanistic insights into how HSC divisional histories 
contribute to functional decline. 
 
Altogether, label retention studies indicate that the contribution of dormant HSCs to daily or 
steady state hematopoiesis is minimal, complementing insights obtained from clonal tracking 
experiments. This reinforces the concept that diversity of quiescent states within the 
HSC/MPP compartment is key for the resilience of blood production, with distinct dynamics 
underlying both a rapid stress response and protection from untoward HSC/MPP exhaustion. 
However, if and how the balance of quiescent states is altered with ageing or disease remains 
poorly characterised. Interestingly, in the ageing brain, changes in the niche enforce increased 
neuronal stem cell quiescence [38]. Future studies will have to consider the further 
complexity that arises in humans with age, due to niche-driven effects, life histories of 
infection/inflammation [39,40] as well as age-related clonal hematopoiesis [19].  
 
 
The importance of the early G1 regulatory network for HSC function 
 
Many studies have investigated whether manipulating the levels of cell cycle regulators can 
influence HSC self-renewal and/or differentiation (reviewed in [41–43]). It is no surprise that 
complex control of the molecular network promoting Rb hyperphosphorylation, and hence 
commitment to division, is absolutely fundamental to regulate how often and how fast HSCs 
exit from quiescence (as discussed above), in addition to the kinetics of successive divisions. 
This network includes, in addition to Rb, CDK4/CDK6, their Cyclin Ds partners, as well as their 
specific CDK inhibitors (p16, p18, p27, p57; Figure 2). 
 
Given the importance of maintaining the life-long capacity for HSC division, it is expected that 
there is a high degree of redundancy between members of the CDK4/CDK6-Rb network, with 
phenotypes observed only when several homologues are genetically deleted in mice [44–46]. 
Constitutive deletion of Cdk6 has minor effects on hematopoiesis, likely due to compensatory 
effects from Cdk4. However, Cdk6 is strictly necessary for HSC exit from quiescence and 
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activation under stress conditions. Cdk6 action during this transition cannot be compensated 
by Cdk4, as demonstrated with constitutive [47] and conditional Cdk6 knock-out models [48].  
 
In addition, when HSC function fails either in the context of an experimental model, or in 
patients, teasing apart whether cell cycle changes are drivers of such loss or merely 
consequences of other signalling events is an ongoing challenge in the field. Indeed, many cell 
cycle regulators possess functions beyond pushing cells towards division [49,50]. CDK6 can 
directly phosphorylate EGR1 [47], a transcription factor involved in HSC function, but also 
TSC2, thereby promoting mTORC1 activity and linking cell cycle with cell growth [51]. CDK6 
can directly block RUNX1 transcriptional activity [52] or contact the chromatin modulating 
NFkB-p65 [53], p16, VEGF-A [54], and p53 antagonists activity [55], broadly affecting HSC 
function in a cell-cycle independent manner.  
 
The whole picture is further complicated by the fact that the cell cycle machinery is activated 
or repressed by a multitude of external stimuli. A very substantial body of work has 
collectively identified more than 100 genes and dozens of environmental components [56] 
that contribute to regulating the delicate balance between HSC quiescence and division. A 
common interpretation of all these studies is that excessive division in vivo almost inevitably 
leads to loss of HSC self-renewal. We would argue that this is an oversimplification. This can 
certainly be driven by exhaustion through excessive division coupled to differentiation (loss 
of self-renewal, “locked out” of quiescence). Nonetheless, failure to divide and produce 
differentiated progeny (“locked in” quiescence) eventually leads to the same failure in blood 
production. Most experimental assays require division to read out HSC function, so caution 
must be taken when interpreting HSC phenotypes with regards to the effects of a particular 
perturbation on the quiescence to division balance. 
 
Is there a causal relationship between G1 length and HSC fate decisions? 
 
A possible causal relationship between cell cycle and fate decisions has long been pursued in 
stem cell biology. The position in the cell cycle may control how cells respond to external 
stimuli [57] and the duration of a particular cell cycle phase [58] may influence cell fate. The 
duration of G1 causally influences cell fate decisions in embryonic stem cells, specifically which 
differentiation route cells take [59–61]. Lengthening of G1 is also associated with commitment 
in neural stem cells [62,63]. Whether similar mechanisms are at play in HSCs is still under 
debate. In human LT-HSCs, overexpression of CDK6 alone leads to shorter early G1 and confers 
a competitive advantage over serial transplantation without causing any overt changes in 
differentiation ability [20]. Overexpression of both CDK4 and Cyclin D1 shortened early G1 
further and increased myeloid differentiation upon xenotransplantation in vivo, but this was 
not supported in vitro [64]. Given the pleiotropic effects of CDKs and Cyclins, it is difficult to 
conclude from these genetic experiments if the slight bias in lineage differentiation is caused 
by different cell cycle lengths or by other factors.  
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We reasoned that we could gain insights into the causal relationship between G1 length and 
human HSC differentiation capacity by lengthening their time of first division. We chose to 
use Palbociclib, a dual and highly specific CDK4/CDK6 inhibitor (hereafter referred to as 
CDK6i), which inhibits the kinase-dependent effects of these proteins without affecting their 
kinase-independent functions. Our group recently identified a subpopulation of long-term 
repopulating cells within the phenotypic human LT-HSC (CD49f+ CD90+) compartment [65], 
that produce lymphoid and myeloid (My) cells but no erythroid (Ery) or megakaryocytic (Meg) 
cells in vitro and upon xenotransplantation [27]. This population, that we termed CLEC9Alo LT-
HSCs (purified as CD34hiCD38-CD45RA-CD90+CD49f+CLEC9Alo) was also characterised by 
shorter quiescence exit and higher CDK6 levels than LT-HSCs or CLEC9Ahi LT-HSCs 
(CD34loCD38-CD45RA-CD90+CD49f+CLEC9Ahi) [27]. We thus sorted single CLEC9Alo LT-HSCs 
and cultured them in conditions that sustain simultaneous differentiation of My, Ery, 
megakaryocytic (Meg) and lymphoid (NK) cells [27], in the presence or absence of 200nM 
CDK6i for the first 3 days (Supplementary Methods). Single CLEC9Ahi LT-HSCs were also 
cultured in parallel as a control. Time to first division was recorded and the differentiation 
output of each cell was determined 3 weeks later by flow cytometry. First, CDK6i lengthened 
the duration of CLEC9Alo LT-HSCs’ first division to that of CLEC9Ahi LT-HSCs (Figure 3A), 
without altering clonogenic efficiency (Figure 3B). Interestingly, upon CDK6i, the proportion 
of CLEC9Alo LT-HSCs’ derived colonies containing NK cells decreased significantly with CDK6i 
(p=0.027); Figure 3C), principally due to a decrease in colonies containing both My and NK 
cells (Figure 3D). However, colony output of CDK6i CLEC9Alo LT-HSCs was still vastly different 
from that of CLEC9Ahi LT-HSCs (Figure 3D). These results suggest that CLEC9Alo LT-HSCs’ 
inability to produce Ery and Meg cells is not caused by their shorter time of quiescence exit. 
Rather we propose that restriction to the myelo-lymphoid lineages is irreversibly determined 
epigenetically and transcriptionally, in line with CLEC9Alo LT-HSCs possessing transcriptional 
features intermediate between CLEC9Ahi LT-HSCs and lymphoid-primed multipotent 
progenitors [27]. However, when G1 was lengthened, CLEC9Alo LT-HSCs commitment to the 
myeloid and lymphoid lineages was significantly imbalanced in vitro. More broadly this 
suggests that changes in cell cycle duration may also influence lineage differentiation in 
hematopoietic stem and progenitor cells and warrant further investigation. 
 
 
Understanding quiescence exit and division ex vivo is essential to improve HSC clinical 
approaches  
 
Recent years have seen important milestones towards clinical applications of HSCs that 
require ex vivo culture of HSCs, such as HSC gene therapy and protocols for HSC expansion 
[66,67]. One critical challenge remains: prolonged culture ex vivo leads to a net decline in HSC 
long-term repopulation capacity [68–70], as a result of divisions shifted to producing daughter 
cells destined for differentiation but also reduced homing. The causes of such decline are 
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multiple and highly dependent on the culture medium composition and culture duration 
[71,72]. Interestingly though, whereas in vivo self-renewing HSCs return to quiescence after 
division, ex vivo HSCs fail to do so. We would argue that understanding how quiescence exit 
and division differ ex vivo from in vivo will be essential to successfully recreate conditions 
maintaining divisions where one (self-renewal) or both (expansion) daughter cells retain HSC 
identity. This will be equally beneficial in the context of gene therapy, where significant 
improvement to gene transfer [73] and editing rates [74] has been achieved by manipulating 
cell-cycle related parameters.   
 
Evidence has accumulated both in vivo [75–78] and ex vivo [79–81] that self-renewal and 
differentiation can under certain circumstances be uncoupled from division. This implies that 
there is no theoretical impossibility for HSC maintenance or expansion ex vivo, as long as 
survival can be guaranteed. Strategies mimicking quiescence-inducing factors normally found 
in the in vivo niche have shown success in minimising the decline in long-term repopulation 
ability of cultured HSCs [82–84], most likely by favouring self-renewing asymmetric divisions. 
Recent strategies with small molecule inhibitors [85,86], aimed at removing differentiation 
factors [71,82,87], limiting accumulation of damaging agents [88] and/or retaining quality 
control mechanisms associated with quiescence in vivo [89] have managed to obtain fully 
functional HSCs in numbers similar or higher than those at the start of the cultures. The most 
impressive expansion to date has been reported to be around 550-fold over 2 months of 
mouse HSC culture with polyvinyl alcohol (PVA) [87]. Of note, no such expansion has been 
obtained with human cells so far, and that all protocols above generate mixed cultures where 
functional HSCs remain a minority. Nonetheless these descriptive studies represent major 
steps forward. All measure HSC expansion by assessing HSC function through transplantation 
rather than mere phenotypic characterisation, which is absolutely essential for this field to 
progress. Altogether, these studies indicate that the entire underlying molecular network, 
stress response regulation and macromolecular organelle biology associated with quiescence 
in vivo should be preserved when aiming to maintain or expand self-renewal ex vivo. 
 
There is much to be learnt from how each of these protocols mechanistically act on HSC 
identity and how they affect quiescence exit and division. For instance, we do not know if 
successful expansion strategies are effectively allowing at least some of the HSCs to return to 
quiescence ex vivo and potentially maintain a hierarchy of cells characterised by accelerated 
division kinetics and progressively decreasing self-renewal as in vivo. There is no doubt that 
better understanding quiescence exit and return to quiescence (or G1) at single cell resolution 
both in vivo as well as in clinically relevant in vitro settings will have a major impact not only 








Quiescence unites but also divides HSCs. Subtle differences in metabolism, quality control 
mechanisms and organelle biology during quiescence lead to seemingly small (several hours) 
yet important differences in division kinetics and distinct division frequency over very long 
timeframes (several months). Together these two parameters control how likely a cell is to 
divide and contribute to blood formation both at steady state and under stress. Given the 
extent to which divisional histories contribute to HSC function [29,31,36,37], and the fact that 
cellular memories of injury may affect subsequent divisions, we propose that diversity in 
quiescent states is perhaps the most relevant aspect of HSC heterogeneity. It is already 
established that the reversible shift from quiescence to division plays a key role in leukemia, 
particularly influencing drug resistance and relapse [90]. HSC quiescent states, quiescence 
exit kinetics and potentially the lineage-biases associated to the latter are likely to shift over 
time, with indications that such shifts may be detrimental in aging and for progression from 
clonal hemopoiesis to overt malignancy. This is a field that we bet will not become dormant 
in the near future. 
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Figure 1: HSC quiescence is a continuum of molecular states associated with specific 
functional features. The cell cycle has four distinct phases indicated by the inner circle, 
Mitosis (M), Gap 1 (G1), the DNA synthesis phase (S) and Gap 2 (G2). Quiescence (G0) is a 
collection of stable states (schematized by colour shading) where Retinoblastoma protein 
(Rb) is unphosphorylated and levels of CDK proteins are low. Dormant HSCs divide very 
infrequently, reside in a particularly deep state of quiescence and are largely resistant to 
activation. Dormant, long term HSCs (LT-HSCs) and short term HSCs (ST-HSCs) reside in 
sequentially shallower states of quiescence, each becoming more primed for cell cycle re-
entry. Quiescence exit (indicated by arrow, arrow thickness indicating strength of activation 
signal required for cell cycle re-entry) in HSCs is predominantly mediated by levels of CDK6 
which form a complex with Cyclin D to allow cell cycle re-entry. During early G1, Rb is 
progressively re-phosphorylated until hyperphosphorylation at the “restriction point” 
(denoted as R) whereby cell lose dependency on extracellular mitogens for cell cycle 
progression and commit to complete the cell cycle. Text indicates molecular and functional 
characteristics associated with different depths of quiescence. ST-HSC: Short term HSCs; LT-
HSC: Long term HSC; ERAD: Endoplasmic Reticulum Associated Degradation; Rb: 
Retinoblastoma protein; R: restriction point. 
 
Figure 2: Quiescence exit and cell cycle re-entry in HSCs is regulated by CDK6/CCND 
mediated Rb phosphorylation. After dephosphorylation in M, G0 and early G1 
unphosphorylated Rb is physically associated to E2F factors blocking the transactivation 
domain and inhibiting cell cycle progression. Upon cell cycle re-entry from quiescence, Rb is 
sequentially phosphorylated by kinase complexes of Cyclin D (CCND) with CDK6 and later 
Cyclin E (CCNE) with CDK2. Hyperphosphorylation of Rb causes a conformational change 
permitting E2F release and transcription of CDK2, Cyclin E (CCNE), Cyclin A (CCNA), MYC and 
other genes involved in cell cycle progression and nucleotide biosynthesis. At this “restriction 
point” (denoted as R) cells lose dependency on extracellular mitogenic signals and commit to 
entering G1/S transition and to complete the cell cycle. Gradients of colour indicate the 
regions of the cell cycle indistinguishable by current functional assays whereas cells can be 
allocated to respective portions of the cell cycle by current methods in fill coloured regions. 
Edge and fill colours for each protein respectively indicate the cell cycle 
progression/frequency of division and long-term repopulation phenotypes observed when 
the corresponding genes were knocked-out as reported in for: p16 [91], p18 [92], p27[93], 
p57 [94], p27/p57 [44], CDK6 [47], CycD triple KO [45], Rb/p107/p130 [46]. White proteins: 





Figure 3: Lengthening the time to first division decreases lymphoid differentiation of Ly-ST-
HSCs. Single cells from the indicated populations were cultured for 3 days in presence or 
absence of CDK6i (Palbociclib, 200 nM), then without CDK6i for 3 weeks. (A-B): Mean time to 
first division (EC50 of non-linear fit of cumulative first division kinetics) (A), and clonogenic 
efficiency of single cells from the indicated populations (B). n= 2 experiments with 
independent CB samples, 144 total cells plated for CD49f+ Subset1, 336 for CD49f+ Subset2, 
192 for CD49f+ Subset2 CDK6i. (C-D): Percentage of colonies containing differentiated cells of 
the indicated lineages (C) and of the indicated type generated by single cells of the indicated 
populations (D). n =2 experiments with independent CB samples, n = 128 colonies from 
CD49f+ Subset1, n = 105 colonies from CD49f+ Subset2, n=161 colonies from CD49f+ Subset2 
CDK6i). Statistical significance shown was calculated by Fisher test using the number of 
colonies obtained from both experiments. (NK: expmt 1 p =0.048, expmt 2 p=0.024; My: 
expmt 1 p=0.039, expmt 2 p=0.056; MyNK: expmt 1 p<0.001, expmt 2 p=0.003; NK only: 
expmt 1 =0.016, expmt 2 p=0.418). Mean ± SEM is shown 
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